Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Repros receives guidance from FDA on Androxal in secondary hypogonadism

Jan. 29, 2010

Palatin Technologies claims MCR ligands for the treatment of sexual dysfunction

Jan. 29, 2010

Studies with tropisetron indicate that 5-HT3R is an antiobesity target

Jan. 29, 2010

Palatin Technologies and AstraZeneca disclose MC4 receptor agonists for treatment of obesity

Jan. 28, 2010

Efficacy and treatment satisfaction of Technosphere Insulin System reported by patients

Jan. 28, 2010

Acrux submits NDA to FDA for Axiron in hypogonadism

Jan. 28, 2010

JCR and Dainippon Sumitomo to terminate comarketing agreement for Growject

Jan. 28, 2010

Dainippon Sumitomo's Metgluco granted Japanese manufacturing and marketing approval

Jan. 28, 2010

FDA reschedules review of NDA for Theratechnologies' tesamorelin

Jan. 27, 2010

FDA approves Novo Nordisk's Victoza for certain adults with type 2 diabetes

Jan. 27, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Fauci’s silence may put him in contempt of Congress
BioWorld
After repeatedly invoking the Fifth Amendment to every question asked during the July 29 hearing of the U.S. Senate Homeland Security Committee, Anthony Fauci,...